HealthFlex
×
  • Home
  • Conference
    • Why should you attend?
    • Scientific Program
    • Speakers
    • Registration
    • Sponsorship
    • Poster Submission
    • Frequently Asked Questions
    • Media Partners
  • Location & Travel
    • The Venue
    • Flight & Hotel
    • Milan Travel Guide
  • Gallery
  • Sponsors
  • Contact
  • Register
Alison Armstrong

Alison Armstrong

Senior Director, Global Head Technical and Scientific Solutions at Merck KGaA

Dr. Alison Armstrong is Senior Director , Global Head of the Technical and Scientific Solutions team. Dr Armstrong has a long history in academic research as a postdoctoral scientist and Research fellow and has been involved in examining the role of viruses in various pathogenic conditions. She has led a number of teams in different divisions within Merck; operational teams, validation and scientific development, and she is currently responsible for a scientific consultancy team with the remit to support clients in technical, scientific, and regulatory issues. During her career Alison has authored many different articles on trends in biosafety testing and is a member of regulatory taskforce groups related to microbiology and virology methods and alternate and rapid technologies. She is an invited speaker at international conferences. Dr. Armstrong holds a PhD in Molecular Virology from the University of Glasgow

__________________

Thu. February 23 | 3pm – CMC considerations for Cell and Gene therapy products

  • Ensuring the safety and quality of cell and gene based therapeutic products is achieved through a multi-tiered approach that examines several factors to establish product safety and manufacturing consistency.
  • Over the past years there has been a dramatic increase in the number of clinical trials involving cellular based therapies. The nature of these novel therapeutic strategies presents testing challenges when compared to traditional therapies that may include limited shelf life and limited testing sample size as well as a need for reduced turnaround times. As a consequence, existing testing approaches are often not suitable for these products.
  • We provide an analysis of the current state of the testing regimes undertaken to ensure product quality. Testing strategies for raw materials, production intermediates and final product are outlined and novel technology including cell characterization, identity and stability, microbial testing and detection of adventitious viruses are reported. The implementation and validation of rapid assay methods and suitability of new testing platforms that allow for streamlining testing and reporting are also discussed and case studies presented.

The BioTech Pharma Summit brings together the movers and shakers in Pharma & Biotech industry from several areas. Uniting niche and top buyers and sellers.

(+351) 915 239 640

client@genapsummit.com

https://biotechpharmasummit.com

Av. da República 676 Office 2, 4430-190 Vila Nova de Gaia

Quick Links

  • GENAP Summit
    • Why should you attend?
    • Registration
    • Scientific Program
    • Speakers
    • Sponsorship
    • Poster Submission
    • Frequently Asked Questions
    • Sponsors
    • Media Partners
  • Location & Travel
    • The Venue
    • Flight & Hotel
  • Gallery
  • Contact GENAP Team

Twitter

BioTech Pharma Summit Follow

biotechsummit
biotechsummit BioTech Pharma Summit @biotechsummit ·
14 Feb

📢We are proud to present Dr. Frank Staal as a keynote speaker for the GENAP Summit 2023 in Milan, Italy
👉Register now at: https://genapsummit.com/
#GENAP23 #atmp #cmc #gct #robotics #hpapi #stemcelltherapy #stemcell #genetherapy

Reply on Twitter 1625484989730111491 Retweet on Twitter 1625484989730111491 Like on Twitter 1625484989730111491 Twitter 1625484989730111491
Terms & Conditions | Privacy Policy

© 2017 Copyright All Rights Reserved | Powered by EPM Group

GENAP Summit is a brand owned by EPM Group, registered company in Portugal. EU VAT ID PT513501312